Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07143019 · ClinicalTrials.gov registry record · NA

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

A NA study of Hemorrhagic Stroke and Aneurysm, Intracranial, sponsored by phenox.

Recruiting
Registry status
NA
Development phase
214
Enrollment target
8
Study locations

NCT07143019 is a NA study of Hemorrhagic Stroke and Aneurysm, Intracranial that is actively recruiting participants, run by phenox. The registered enrollment target is 214 participants, below the 10,362-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07143019, a NA study of Hemorrhagic Stroke and Aneurysm, Intracranial, is actively recruiting participants, sponsored by phenox.

RECRUITING
Registry status
NA
Development phase
214 participants
Enrollment target
8
Study locations

Study Summary

To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC flow diverter in the treatment of wide-necked intracranial aneurysms.

Interventions

  • DEVICE Flow diversion

Study Locations (8)

Colorado

  • University of Colorado Anschutz - Aurora
  • Swedish Medical Research Center - Englewood

New York

  • UBNS - Buffalo
  • North Shore University Hospital - Northwell Health - Manhasset

Arizona

  • Barrow Neurological Institute - Phoenix

Florida

  • Baptist Health Research Institute - Jacksonville

Massachusetts

  • Tufts Medical Center - Boston

Washington

  • University of Washington - Harborview Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 214 participants
Start Date 2026-02
Est. Completion 2032-06
Phase NA

Sponsor

phenox

2 total trials

What the Registry Record Tells You About NCT07143019

The ClinicalTrials.gov registry entry for NCT07143019 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 10,362-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (98% lower). The listed sponsor is phenox, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Hemorrhagic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Flow diversion is the first listed.

NCT07143019 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Colorado, New York, Arizona.

Frequently Asked Questions

What is clinical trial NCT07143019 about?

NCT07143019 is a clinical study titled "The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms". To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC flow diverter in the treatment of wide-necked intracranial aneurysms.

What is the current status of trial NCT07143019?

This trial is currently recruiting. It is a NA study. The enrollment target is 214 participants. The study started on 2026-02. Estimated completion is 2032-06.

What conditions does trial NCT07143019 study?

This clinical trial studies the following conditions: Hemorrhagic Stroke, Aneurysm, Intracranial, Brain Aneurysm, Saccular Aneurysm, Fusiform Aneurysm.

What interventions are being tested in trial NCT07143019?

The interventions under investigation include: Flow diversion (DEVICE).

Who is sponsoring clinical trial NCT07143019?

This trial is sponsored by phenox, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07143019 being conducted?

This trial has 8 study locations across Arizona, Colorado, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemorrhagic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.